TITLE:
Study of Karenitecin (BNP1350) in Patients With Brain Tumors

CONDITION:
Brain Neoplasms

INTERVENTION:
Karenitecin (BNP1350)

SUMMARY:

      The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a
      treatment of adults with brain tumors.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        -  Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or
             recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic
             oligodendroglioma.

          -  Evidence of measurable recurrent or residual primary CNS neoplasm.

          -  An interval of at least 3 weeks between prior surgical resection or 6 weeks between
             prior radiotherapy or chemotherapy, and enrollment on this protocol unless there is
             unequivocal evidence of tumor progression after surgery, radiotherapy, or
             chemotherapy.

          -  Hematocrit > 29%, ANC > 1,500, platelets > 125,000

          -  Serum creatinine < 1.5 mg/dl, BUN < 25 mg/dl, serum SGOT and bilirubin < 1.5 times
             upper limit of normal

          -  Negative pregnancy test for female patients
      
